Pervaiz Butt Salman, Kakar Vivek, Abdulaziz Salman, Razzaq Nabeel, Saleem Yasir, Kumar Arun, Ashiq Fazil, Ghisulal Praveen, Thrush Aaron, Malik Sadaf, Griffin Mairead, Amir Mahanoor, Khan Umar, Salim Ashal, Zoumot Zaid, Mydin Izanee, Aljabery Yazan, Bhatnagar Gopal, Bayrak Yusuf, Obeso Andres, Ahmed Usman
Interim Manager Perfusion Services, Heart Vascular and Thoracic Institute, Cleveland Clinic, PO BOX 112412, Abu Dhabi, United Arab Emirates.
Director ECMO Program, Critical Care Institute, PO BOX 112412, Abu Dhabi, United Arab Emirates.
J Extra Corpor Technol. 2024 Dec;56(4):191-202. doi: 10.1051/ject/2024023. Epub 2024 Dec 20.
Lung transplantation (LTx) is a critical intervention for patients with end-stage lung disease. However, challenges such as donor organ scarcity and post-transplant complications significantly affect its success. Recent advancements in Extracorporeal Membrane Oxygenation (ECMO) have shown promise in improving the outcomes and expanding eligibility for LTx.
A comprehensive literature review was conducted, focusing on studies that explore the use of ECMO in lung transplantation. A thorough search of relevant studies on ECMO and LTx was conducted using multiple scholarly databases and relevant keywords, resulting in 73 studies that met the inclusion criteria. Sources included peer-reviewed journals and clinical trial results, with emphasis on articles captured recent advancements in ECMO technology and techniques.
ECMO has been crucial in supporting patients before, during, and after LTx. It serves as a bridge to transplantation by maintaining pulmonary and circulatory stability in critically ill patients awaiting donor organs. ECMO also aids in the evaluation of marginal donor lungs and supports patients through acute post-transplant complications. Recent technological advancements have improved the safety and efficacy of ECMO, further solidifying its role in LTx.
In conclusion, this review underscores ECMO's critical role in enhancing outcomes across all stages of lung transplantation. Its various configurations and strategies have shown promise in stabilizing critically ill patients and improving transplant success rates. Looking ahead, it's important to gather more information about the long-term outcomes and potential complications associated with ECMO use. More research and data collection will help us understand the benefits and risks better, leading to improved decision-making and patient care in this field.
肺移植(LTx)是终末期肺病患者的关键治疗手段。然而,供体器官短缺和移植后并发症等挑战严重影响了其成功率。体外膜肺氧合(ECMO)的最新进展在改善肺移植结局和扩大肺移植适应证方面显示出了前景。
进行了一项全面的文献综述,重点关注探索ECMO在肺移植中应用的研究。使用多个学术数据库和相关关键词对有关ECMO和肺移植的相关研究进行了全面检索,共筛选出73项符合纳入标准的研究。资料来源包括同行评审期刊和临床试验结果,重点关注阐述ECMO技术和方法最新进展的文章。
ECMO在肺移植术前、术中和术后对患者的支持方面发挥了关键作用。它通过维持等待供体器官的重症患者的肺和循环稳定性,成为移植的桥梁。ECMO还有助于评估边缘供肺,并支持患者度过移植后急性并发症期。最近的技术进步提高了ECMO的安全性和有效性,进一步巩固了其在肺移植中的作用。
总之,本综述强调了ECMO在改善肺移植各阶段结局方面的关键作用。其各种配置和策略在稳定重症患者和提高移植成功率方面显示出了前景。展望未来,重要的是收集更多关于ECMO使用的长期结局和潜在并发症的信息。更多研究和数据收集将有助于我们更好地理解其益处和风险,从而在该领域改善决策和患者护理。